Drug companies, healthcare providers look to Obama to name new FDA leader
WASHINGTON Healthcare personnel, drug companies and others await President-elect Barack Obama’s decision in appointing new, strong leadership to the Food and Drug Administration, reports out of Washington said today. It is expected that current FDA commissioner Andrew von Eschenbach will leave the position in January following Obama’s inauguration.
The position of FDA commissioner has had a revolving door over the course of the last eight years while the agency has faced controversies over the safety of approved drugs and recalls of tainted food, according to published reports.
The FDA is responsible for the review of more than $1 trillion annually in foods, medicines, devices and other items for consumption. With a responsibility to public health and the U.S. economy that great, strong leadership and a deep understanding of the FDA’s responsibilities to consumers, companies and Congress will require the appointment of someone with a strong background in science or medicine, who is prepared to make informed decisions on products, analysts have said.
“The FDA’s going to have to re-earn the trust of the public,” Sidney Wolfe, director for the consumer group Public Citizen’s Health Research Group, told Reuters.
Reports also stated that drug makers would like to see effective leadership in the position of commissioner. More drug makers have complained recently of delays in getting FDA approvals on new drugs.
Still, it could take several months to a year-and-a-half before President-Elect Obama names a new commissioner, sources said.
AHIMA applauds Barack Obama for campaign success
CHICAGO The American Health Information Management Association has congratulated Barack Obama on his election as president of the United States, calling for reform of the healthcare system.
“Given the president-elect’s strong statements in support of health information as a key to expanding healthcare coverage while improving quality and controlling costs‹most recently during his infomercial last week—AHIMA is understandably optimistic,” AHIMA chief executive officer Linda Kloss said in a statement. “We urge the Obama administration to pursue the imperative of a 21st century health information platform that offers providers, payers and patients the accurate, integrated and secure electronic information they need to make decisions of utmost importance.”
GlaxoSmithKline consolidates U.S. headquarters, announces layoffs of 1,000
PHILADELPHIA GlaxoSmithKline, the maker of Abreva, Aquafresh toothpastes, Nicorette, Sensodyne and Tums will cut its workforce by about 1,800 jobs and make Research Triangle Park in North Carolina its permanent North American headquarters, replacing the current U.S. headquarters in Philadelphia, reports said today.
GlaxoSmithKline has had duel headquarters in the United States since the merger between Glaxo Wellcome and SmithKline Beecham was finalized in 2000, The Wall Street Journal today reported.
Today, GSK said that it will cut 1,800 positions, laying off about 1,000 people and eliminating hundreds of vacant positions, reports said.
GSK’s global headquarters are in London. The company is currently in the midst of belt-tightening in many departments due to growing pressure from the quickly expanding generic drug market and a decline in drug sales.